{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:47:20Z","timestamp":1767134840255,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":37,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd003960.pub2","type":"reference-entry","created":{"date-parts":[[2004,1,29]],"date-time":"2004-01-29T13:02:36Z","timestamp":1075381356000},"source":"Crossref","is-referenced-by-count":29,"title":["Tegaserod for the treatment of irritable bowel syndrome"],"prefix":"10.1002","author":[{"given":"BW","family":"Evans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WK","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DJ","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PJ","family":"Whorwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,1,26]]},"reference":[{"key":"10.1002\/14651858.CD003960.pub2-BIB1|cit1","unstructured":"Novartis Pharmaceuticals Corporation East Hanover New Jersey http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3627b1a.pdf 1 93"},{"key":"10.1002\/14651858.CD003960.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1572-0241.2002.05692.x","article-title":"Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms","volume":"97","author":"Fidelholtz","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1002\/14651858.CD003960.pub2-BIB3|cit3","series-title":"Gut","first-page":"A217","author":"Rawls","year":"2000"},{"key":"10.1002\/14651858.CD003960.pub2-BIB4|cit4","series-title":"Digestion","first-page":"735 (abstract B","author":"Hamling","year":"1998"},{"key":"10.1002\/14651858.CD003960.pub2-BIB5|cit5","unstructured":"Novartis Pharmaceuticals Corporation East Hanover New Jersey http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3627b1a.pdf 1 93"},{"key":"10.1002\/14651858.CD003960.pub2-BIB7|cit6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gut.52.5.671","volume":"52","author":"Kellow","year":"2003","journal-title":"Gut"},{"key":"10.1002\/14651858.CD003960.pub2-BIB6|cit7","series-title":"Gut","first-page":"A11 (abstract 0","article-title":"Tegaserod is an effective therapy for non-diarrhea irritable bowel syndrome in an Asian-Pacific population","author":"Kellow","year":"2002"},{"key":"10.1002\/14651858.CD003960.pub2-BIB8|cit8","series-title":"Gastroenterology","first-page":"A1027 (abstract","author":"Lefkowitz","year":"1999"},{"key":"10.1002\/14651858.CD003960.pub2-BIB9|cit9","first-page":"1","author":"Novartis Pharmaceuticals Corporation East","journal-title":"http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3627b1a.pdf"},{"key":"10.1002\/14651858.CD003960.pub2-BIB10|cit10","series-title":"Gut","first-page":"A260 (abstract","author":"Whorwell","year":"1999"},{"key":"10.1002\/14651858.CD003960.pub2-BIB12|cit11","series-title":"Gut","first-page":"A260 (abs P0965","author":"Krumholz","year":"1999"},{"key":"10.1002\/14651858.CD003960.pub2-BIB15|cit12","series-title":"Gut","first-page":"A217 (abstract","article-title":"Tegaserod rapidly improves abdominal pain, bloating and bowel function in patients with C-IBS","author":"Lefkowitz","year":"2000"},{"key":"10.1002\/14651858.CD003960.pub2-BIB11|cit13","series-title":"Am J Gastroenterol","first-page":"2676 (abstract","author":"Lefkowitz","year":"1999"},{"key":"10.1002\/14651858.CD003960.pub2-BIB14|cit14","first-page":"1","author":"Novartis Pharmaceuticals Corporation East","journal-title":"http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3627b1a.pdf"},{"key":"10.1002\/14651858.CD003960.pub2-BIB13|cit15","series-title":"Gut","first-page":"A258 (abstract","author":"Schmitt","year":"1999"},{"key":"10.1002\/14651858.CD003960.pub2-BIB17|cit16","first-page":"A175 (abs 1000)","volume":"116 (Suppl 2)","author":"Mueller-Lissner","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003960.pub2-BIB16|cit17","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1046\/j.1365-2036.2001.01094.x","article-title":"Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation","volume":"15","author":"Muller-Lissner","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/14651858.CD003960.pub2-BIB18|cit18","first-page":"1","author":"Novartis Pharmaceuticals Corporation East","journal-title":"http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3627b1a.pdf"},{"key":"10.1002\/14651858.CD003960.pub2-BIB20|cit19","series-title":"Gastroenterology","first-page":"A22 (abstract 1","author":"Lefkowitz","year":"2001"},{"key":"10.1002\/14651858.CD003960.pub2-BIB19|cit20","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1046\/j.1365-2036.2002.01372.x","article-title":"A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation","volume":"16","author":"Novick","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/14651858.CD003960.pub2-BIB21|cit21","series-title":"Gastroenterology","first-page":"Abstract 5340","author":"Appel-Dingemanse","year":"2000"},{"key":"10.1002\/14651858.CD003960.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0016-5085(00)70251-4","volume":"118","author":"Prather","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003960.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1046\/j.1365-2036.2002.01347.x","volume":"16","author":"Tougas","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/14651858.CD003960.pub2-BIB24|cit24","series-title":"Digestive Disease Week","first-page":"Abs S1017","author":"Lin","year":"2003"},{"key":"10.1002\/14651858.CD003960.pub2-BIB25|cit25","series-title":"Digestive Disease Week","first-page":"Abs T1804","author":"Munoz","year":"2003"},{"key":"10.1002\/14651858.CD003960.pub2-BIB26|cit26","series-title":"Digestive Disease Week","first-page":"Abs M1645","author":"Nyhlin","year":"2003"},{"key":"10.1002\/14651858.CD003960.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2001.21908","article-title":"Management of the irritable bowel syndrome","volume":"120","author":"Camilleri","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003960.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/bmj.310.6973.171","article-title":"Irritable bowel, irritable body, or irritable brain?","volume":"310","author":"Farthing","year":"1995","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003960.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003495-199856010-00002","article-title":"New drugs in the management of the irritable bowel syndrome","volume":"56","author":"Farthing","year":"1998","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD003960.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1016\/S0002-9343(99)00276-4","article-title":"Diagnostic criteria for the irritable bowel syndrome","volume":"107","author":"Hammer","year":"1999","journal-title":"Am J Med"},{"key":"10.1002\/14651858.CD003960.pub2-BIB31|cit31","first-page":"1","article-title":"British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome","volume":"47 (Suppl 2)","author":"Jones","year":"2000","journal-title":"Gut"},{"key":"10.1002\/14651858.CD003960.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1111\/j.1572-0241.2002.05986.x","article-title":"Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects","volume":"97","author":"Morganroth","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1002\/14651858.CD003960.pub2-BIB33|cit33","unstructured":"Novartis Pharmaceuticals Corporation East Hanover New Jersey http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3627b1a.pdf 1 93"},{"key":"10.1002\/14651858.CD003960.pub2-BIB34|cit34","series-title":"Gut","first-page":"A45 (abstract 1","article-title":"Irritable bowel syndrome diagnosed in primary care: how many patients fulfil Rome II criteria?","author":"Robinson","year":"2001"},{"key":"10.1002\/14651858.CD003960.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(02)09712-X","article-title":"Irritable bowel syndrome: a little understood organic bowel disease","volume":"360","author":"Talley","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003960.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/00042737-199707000-00008","article-title":"Irritable bowel syndrome: the view from general practice","volume":"9","author":"Thompson","year":"1997","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD003960.pub2-BIB37|cit37","first-page":"II69","article-title":"Design of treatment trials for functional gastrointestinal disorders","volume":"Suppl II","author":"Zanten","year":"1999","journal-title":"Gut"}],"updated-by":[{"DOI":"10.1002\/14651858.cd003960.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2007,10,17]],"date-time":"2007-10-17T00:00:00Z","timestamp":1192579200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD003960.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:28:11Z","timestamp":1628530091000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003960.pub2"}},"subtitle":[],"editor":[{"given":"Beti","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2004,1,26]]},"references-count":37,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003960.pub2","relation":{},"subject":[],"published":{"date-parts":[[2004,1,26]]}}}